Equities

Mustang Bio Inc

MBIO:NAQ

Mustang Bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.13
  • Today's Change-0.005 / -3.99%
  • Shares traded922.27k
  • 1 Year change-98.03%
  • Beta1.6560
Data delayed at least 15 minutes, as of Jun 14 2024 21:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.

  • Revenue in USD (TTM)0.00
  • Net income in USD-40.10m
  • Incorporated2015
  • Employees80.00
  • Location
    Mustang Bio Inc377 PLANTATION STREETWORCESTER 01605United StatesUSA
  • Phone+1 (781) 652-4500
  • Fax+1 (302) 531-3150
  • Websitehttps://www.mustangbio.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Nexien Biopharma Inc0.00-246.18k1.43m0.00---------0.0038-0.00380.00-0.00480.00-------679.40-860.53---1,653.53-----------1.77--------42.22------
Dermata Therapeutics Inc0.00-8.69m1.44m8.00--4.46-----24.67-24.670.000.57170.00----0.00-120.05---146.08--------------0.00------18.90------
180 Life Sciences Corp0.00-16.24m1.46m4.00---------41.54-41.540.00-1.120.00----0.00-176.90-42.39-354.57-56.41-----------385.88--------48.52------
Target Group Inc5.64m228.87k1.48m46.0018.46--1.390.26260.00010.00010.0088-0.01150.7648.60124.27115,104.103.10-37.99---78.7643.71--4.06-586.970.07360.01493.10----577.8392.84---58.54--
Bluejay Diagnostics Inc0.00-9.74m1.48m10.00--0.4072-----7.68-7.680.001.250.00----0.00-122.06---149.68--------------0.0048---100.00---7.07------
Panacea Life Sciences Holdings Inc2.76m-7.67m1.57m40.00------0.5688-0.4554-0.45540.164-0.52550.15371.6210.1369,098.25-42.65-69.04---225.03-139.49-181.62-277.51-505.410.0285-2.124.79--46.59--12.33------
Mallinckrodt PLC1.91bn-1.49bn1.60m2.80k------0.0008-161.65-161.6389.6355.440.40621.574.94681,821.40-31.61-12.49-36.10-15.8526.2235.68-77.83-44.381.63-0.34560.6164---2.53-10.31-83.00------
Mustang Bio Inc0.00-40.10m1.63m80.00---------4.55-4.550.00-0.47570.00----0.00-90.93-70.02-138.05-79.98-----------15.88--------33.44---60.75--
Stemcell Holdings Inc9.98m3.10m1.64m------0.50080.16450.000080.000080.00030.00021.12--5.20--34.90--68.19--77.19--31.04------0.00--85.10--71.82------
Link Reservations Inc0.00-480.90k1.70m0.00---------46.51-46.510.00-13.990.00-------246.84-----------------2.43---------22.69------
InVitro International716.89k6.22k1.71m16.00214.292.33--2.380.00040.00040.04020.03211.15------0.9957.891.098.83----0.86765.90---------5.111.33-87.77-16.14----
CanaQuest Medical Corp0.00-801.66k1.71m-----------0.051-0.0510.00-0.03680.00-------1,084.38--------------------------57.42------
SOHM Inc-100.00bn-100.00bn1.72m--------------------------------------------------------------
ENDRA Life Sciences Inc0.00-9.89m1.78m21.00--0.3058-----1.26-1.260.000.33880.00----0.00-168.89-132.00-228.29-157.28------------0.00------23.67---19.46--
Hi-Great Group Holding Co101.27k-113.56k1.78m--------17.58-0.0011-0.00110.001-0.00110.78870.8027-----88.44------48.60---112.14--0.0197-48.81-----47.32---3,789.70------
Data as of Jun 14 2024. Currency figures normalised to Mustang Bio Inc's reporting currency: US Dollar USD

Institutional shareholders

6.91%Per cent of shares held by top holders
HolderShares% Held
Armistice Capital LLCas of 31 Mar 2024210.00k1.80%
The Vanguard Group, Inc.as of 31 Mar 2024203.71k1.75%
BlackRock Fund Advisorsas of 31 Mar 202498.48k0.84%
Koss-Olinger Consulting LLCas of 31 Dec 202396.37k0.83%
Geode Capital Management LLCas of 31 Mar 202448.40k0.42%
Antecedo Asset Management GmbHas of 31 Dec 202346.67k0.40%
Renaissance Technologies LLCas of 31 Mar 202435.39k0.30%
Virtu Americas LLCas of 31 Mar 202430.18k0.26%
HighTower Advisors LLCas of 31 Mar 202419.71k0.17%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202417.04k0.15%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.